New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2014
09:34 EDTADMP, GSK, MMMAdamis completes asset acquisition from 3M Company
Adamis Pharmaceuticals (ADMP) announced that at a closing held on December 27, 2013, it made a final payment of $7M to fully acquire from 3M Company (MMM) and 3M Innovative Properties certain intellectual property and assets relating to 3M's Taper Dry Powder Inhaler technology under development for the treatment of asthma and chronic obstructive pulmonary disease. Adamis intends to utilize the assets initially to undertake efforts to develop a dry powder inhaler device for the treatment of asthma and COPD to deliver the same active ingredients as GlaxoSmithKline's (GSK) Advair Diskus. The intellectual property includes patents, patent applications and other intellectual property relating to the Taper assets.
News For ADMP;MMM;GSK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 25, 2015
12:13 EDTGSKGlaxoSmithKline sees Novartis transaction closing next week
Subscribe for More Information
11:24 EDTGSKGlaxoSmithKline announces return of alli to retail stores
Subscribe for More Information
February 24, 2015
09:13 EDTADMPAdamis announces pharmacokinetic study results for APC-1000
Subscribe for More Information
February 23, 2015
14:44 EDTMMM3M confirms agreement to acquire Polyporeís Separations Media business for $1B
3M (MMM) announced that it has entered into a definitive agreement with Polypore International (PPO) to acquire the assets and liabilities associated with Polyporeís Separations Media business for a total purchase price of $1B. Polyporeís Separations Media business is a leading provider of microporous membranes and modules for filtration in the life sciences, industrial and specialty segments with trailing 12-month sales of $210M as of Sept. 27, 2014. Separately, Asahi Kasei has announced that it has entered into a definitive merger agreement to acquire Polyporeís Energy Storage business. Both transactions are subject to regulatory approvals and customary closing conditions. In addition, both transactions are conditioned on 3Mís transaction with Polypore closing immediately prior to the closing of Asahi Kaseiís transaction with Polypore.
13:33 EDTGSKRBS could name Howard Davies as chairman this week, FT reports
Royal Bank of Scotland (RBS) could name Howard Davies as its chairman as early as Thursday, when the bank reports its full-year results, the Financial Times reports. Davies is currently chairman of insurance business Phoenix Group and chairs Morgan Stanley's (MS) risk committee. Current RBS Chairman Philip Hampton is set to become GlaxoSmithKline's (GSK) chairman as early as this summer. Reference Link
12:21 EDTMMMOn The Fly: Midday Wrap
Subscribe for More Information
11:17 EDTGSKFTC puts conditions on Novartis's proposed acquisition of GSK oncology drugs
According to the FTC, Global pharmaceutical company Novartis (NVS) has agreed to divest all assets related to its BRAF and MEK inhibitor drugs, currently in development, to Boulder, Colorado-based Array BioPharma (ARRY) to settle charges that Novartisís $16B acquisition of GlaxoSmithKlineís (GSK) portfolio of cancer-treatment drugs would likely be anticompetitive...If the acquisition goes forward as proposed, Novartis would likely delay or terminate development of both its BRAF and MEK inhibitors, as well as the combination product. For that reason, Novartisís acquisition of GSKís portfolio of cancer-treatment drugs would likely cause significant competitive harm in the U.S. markets for both the BRAF and MEK inhibitors, ultimately raising prices for consumers and depriving them of potentially superior products. Under the terms of the proposed consent agreement, Novartis is required to provide transitional services to Array BioPharma to ensure that development of the BRAF and MEK inhibitors continues uninterrupted and that competition in BRAF and MEK inhibitor markets is not reduced. Reference Link
05:34 EDTMMM3M expects acquisition of Polypore business to be dilutive to earnings
Subscribe for More Information
05:31 EDTMMM3M acquires Polypore's Separatoins Media Segment for $1B
As an integrated step in Polypore's (PPO) sale to Asahi Kasei for $60.50, immediately prior the transaction, 3M (MMM) will acquire the assets of Polypore's Separations Media segment for approximately $1band Asahi Kasei will receive the cash proceeds from the asset sale. The definitive agreements require that the sale of the Polypore and the integrated sale of the Separations Media segment close after closing conditions for both transactions have been satisfied and that the closings of the transactions are conditioned upon one another.
05:29 EDTMMMPolypore agrees to sell company for $60.50 per share
Subscribe for More Information
February 20, 2015
07:23 EDTGSKAbbVie replaces Pfizer as top global pharma pick at Jefferies
Subscribe for More Information
07:08 EDTGSKAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.
February 19, 2015
10:01 EDTMMM3M acquires health care products manufacturer Ivera Medical
3M announced that it has entered into a definitive agreement to acquire Ivera Medical, a manufacturer of health care products that disinfect and protect devices used for access into a patientís bloodstream. Terms of the transaction were not disclosed. Ivera employs approximately 60 people and has annual sales of approximately $30M. The transaction is expected to close in the first half of 2015. On a GAAP reported basis, 3M estimates the acquisition to be neutral to earnings in the first 12 months following completion of the transaction.
08:23 EDTGSKGlaxoSmithKline weakness creates buying opportunity, says Argus
Subscribe for More Information
February 18, 2015
07:07 EDTMMMBarclays to hold a conference
Industrial Select Conference is being held in Miami on February 18-19.
February 17, 2015
07:38 EDTGSKGlaxo replaces head of struggling U.S. drug unit, Bloomberg reports
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use